Cargando…
Ovarian Cancer Immunotherapy: Turning up the Heat
Epithelial ovarian cancer (EOC) is the leading cause of death among gynecological malignancies. Despite surgery and chemotherapy, 5-years survival rates have improved only modestly over the past few decades remaining at 45% for advanced stages. Therefore, novel therapies are urgently needed. The pre...
Autores principales: | Ghisoni, Eleonora, Imbimbo, Martina, Zimmermann, Stefan, Valabrega, Giorgio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628106/ https://www.ncbi.nlm.nih.gov/pubmed/31208030 http://dx.doi.org/10.3390/ijms20122927 |
Ejemplares similares
-
Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy
por: Giannone, Gaia, et al.
Publicado: (2020) -
Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives
por: Borella, Fulvio, et al.
Publicado: (2020) -
Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity
por: Mittica, Gloria, et al.
Publicado: (2017) -
Adoptive immunotherapy against ovarian cancer
por: Mittica, Gloria, et al.
Publicado: (2016) -
Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer
por: Giannone, Gaia, et al.
Publicado: (2019)